Myeloproliferative neoplasms (MPNs) driver mutations are usually found in JAK2, MPL, and CALR genes; however, 10%-15% of cases are triple negative (TN). A previous study showed lower rate of JAK2 V617F in primary myelofibrosis patients exposed to low doses of ionizing radiation (IR) from Chernobyl accident. To examine distinct driver mutations, we enrolled 281 Ukrainian IR-exposed and unexposed MPN patients. Genomic DNA was obtained from peripheral blood leukocytes. JAK2 V617F, MPL W515, types 1-and 2-like CALR mutations were identified by Sanger Sequencing and real time polymerase chain reaction. Chromosomal alterations were assessed by oligo-SNP microarray platform. Additional genetic variants were identified by whole exome and targeted sequencing. Statistical significance was evaluated by Fisher's exact test and Wilcoxon's rank sum test (R, version 3.4.2). IR-exposed MPN patients exhibited a different genetic profile vs unexposed: lower rate of JAK2 V617F (58.4% vs 75.4%, P = .0077), higher rate of type 1-like CALR mutation (12.2% vs 3.1%, P = .0056), higher rate of TN cases (27.8% vs 16.2%, P = .0366), higher rate of potentially pathogenic sequence variants (mean numbers: 4.8 vs 3.1, P = .0242). Furthermore, we identified several potential drivers specific to IR-exposed TN MPN patients: ATM p.S1691R with copy-neutral loss of heterozygosity at 11q; EZH2 p.D659G at 7q and SUZ12 p.V71 M at 17q with copy number loss. Thus, IRexposed MPN patients represent a group with distinct genomic characteristics worthy of further study.
| INTRODUCTION
Ionizing radiation (IR) is a well-established human carcinogen that can cause genetic mutations or copy number alterations. Exposure to IR is associated with the induction of solid cancers and hematological malignancies including myeloproliferative neoplasms (MPNs).
1,2 On
April [25] [26] 1986 , the Chernobyl nuclear power plant accident at reactor 4 occurred in Ukraine, classified as a level 7 event by the International Nuclear Event Scale. Over 500 000 people were involved in clean-up work following the accident during 1986-1991. Nearly 400 million people resided in territories that were contaminated with dangerous levels of radioactivity from April to July 1986. About 5 million people still live with dangerous levels of radioactive contamination in Ukraine, Belarus, and European Russia, thus the hematologic effects of IR are of ongoing concern.
Philadelphia-chromosome negative chronic MPNs are clonal diseases of hematopoietic stem cells that encompass polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Today the cause of MPNs can be identified on the molecular level in the majority of cases. 3, 4 Acquired somatic mutations that drive the myeloproliferative phenotype usually arise in a mutually exclusive manner in 3 known genes: Janus Kinase 2 (JAK2), Thrombopoietin
Receptor (MPL), and Calreticulin (CALR), all of which activate JAK/STAT signaling. [4] [5] [6] The most frequent mutation of the JAK2 gene, JAK2
V617F, is associated with >95% of PV cases and with 50%-60% of ET and PMF cases. [5] [6] [7] [8] The frequencies of the CALR gene mutations in patients with ET and PMF vary from 14% to 31% and from 12% to 35% of cases, respectively, as shown in meta-analysis of 19 studies. 9 A small proportion, 5%-10%, of MPN patients has activating mutations in the MPL gene. 5 However, somatic mutations of JAK2, MPL, or CALR gene are absent in 10%-15% of MPN patients, and this group is in a molecular diagnostic gap. 4, 5, 10, 11 Thus, other molecular mechanisms might be involved in disease development in this group of patients. Numerous additional mutations have been described in MPNs, which can be mutually exclusive or co-exist with 1 of the 3 usual driving mutations. These include mutations affecting genes involved in cell signaling (c-CBL, SOCS, LNK, PTPN11, FLT3, KIT, KRAS, and NF1), tumor suppression (CEBPA, NPM1, and RUNX1), RNA maturation and slicing (SF3B1, SRSF2, and U2AF1), epigenetic regulation (ATRX, DAXX, TET2, DNMT3A, EZH2, and ASXL1), or leukemic transformation (IDH1/2, NRAS/KRAS, TP53, and RUNX1).
12-16
Rapidly proliferating hematopoietic tissue is the most radiosensitive in a human body. When exposed to IR at doses in excess of 1-2
Gy, the sequence of predictable events appears within hours or days and is referred to as acute radiation syndrome which includes hematopoietic, gastrointestinal and neurovascular subsyndromes. The severity and duration of bone marrow depression is dose dependent at doses >1 Gy (deterministic or nonstochastic effects). Late IR effects caused by lower doses can manifest months or years after irradiation and do not exhibit a dose threshold (nondeterministic or stochastic effects). This study is focused on these late stochastic IR effects. The fundamental alterations (DNA base damages and changes, DNA-DNA and DNA-protein cross linking, single-, and double-strand breaks) that lead to late effects occur immediately after exposure. Radiogenic acute leukemia is one of the best studied neoplasms with the shortest minimal latent period and peak-incidence after IR exposure (2 and 5-7 years, respectively). In contrast, the minimal latent period for IRinduced multiple myeloma is approximately 20 years with unknown peak-incidence time after exposure. For IR-induced MPNs the latent period and peak-incidence after exposure are unknown. 17, 18 In this study, we provide a molecular and cytogenetic characterization of patients who developed MPN's following exposure to IR during the Chernobyl nuclear accident, in comparison with other Ukrainian MPN patients who did not report significant exposure to IR. A preliminary study of the same cohort of patients showed that the JAK2 V617F mutation was less common in IR-exposed PMF patients than in unexposed PMF patients. 1, 19 Thus, we hypothesized that IR-exposed MPN patients would exhibit a lower rate of the usual driver mutations, but would exhibit novel mutations and genomic alterations which could contribute to MPN development and evolution. In this study, we confirmed this hypothesis and identified combinations of sequence variants and copy number variants that may serve as drivers of MPN in IR-exposed patients.
2 | METHODS System. The raw sequencing data was processed to remove any adaptor, PCR primers and low-quality reads using trimmomatic program. 22 The quality of the reads was checked using FastQC program. 23 Highquality reads were aligned against human genome using BurrowsWheeler Alignment algorithm in paired manner. 24 As a reference, GRCh38 human genome assembly was used. Variant calling was performed using Haplotype caller function in GATK workflow. 25 Further annotation of variants was performed using the ANNOVAR tool. 26 Nonsynonymous nucleotide variants with adequate read depth (at least 5 variant reads and variant read count >5% of reads) were compared between MPN patients and controls (healthy IR-exposed and unexposed groups).
| Patients and controls

| Statistical analysis
Statistical significance for categorical variables and continuous variables were evaluated by Fisher's exact test and Wilcoxon's rank sum test using R, version 3.4.2.
3 | RESULTS
| Demographic and clinical features of MPN patients
We studied 281 patients (106 PV patients, 58 ET patients, 108 PMF patients and 9 MPN, unclassifiable). Supporting Information Tables S2 and S3 report the demographic, clinical, and hematologic features of IR-exposed and unexposed MPN patients at the time of diagnosis, classified by disease subtype according to the World Health Organization (WHO) classification of 2016. 27 Overall, 151 males and 128 females were enrolled in the study. There were more males than females among IR-exposed MPN patients (P < .0001), the same pattern of sex distribution was observed in disease subtypes of IRexposed MPN patients including PV, ET, and PMF patients. This is consistent with more males being involved in the cleanup work of the Chernobyl nuclear accident consequences. IR-exposed MPN patients were older (P < The clinical features of both groups, IR-exposed and unexposed MPN patients (cases of thrombosis, splenomegaly, transfusion dependence, transformation to acute leukemia), were similar and comparable to the reported data in retrospective studies. 10, [28] [29] [30] [31] However, more PMF IR-exposed patients were transfusion dependent (32.4%), than PMF unexposed patients (14.1%) (P = .042), indicating enhanced severity of radiation-associated PMF. No significant difference in the rate of transformation to acute leukemia was observed (Supporting Information Table S2 ). However, for most MPN patients the follow up period was <10 years from diagnosis, which may not be sufficient time to observe leukemia transformation.
3.2 | Frequencies of the usual driver mutations in JAK2, MPL, and CALR genes in IR-exposed and IRunexposed MPN patients
We next carried out a series of studies to identify the spectrum of genomic alterations in IR-exposed vs unexposed MPN patients ( Figure 1A ). We first tested for the presence of the JAK2 V617F mutation. There were significantly more JAK2 V617F-positive cases (75.4%) among IR-unexposed MPN patients, compared with IRexposed patients (58.4%) (P = .0077) ( Figure 1B ; Supporting Information Table S4 ). This did not appear to reflect a higher prevalence of PV among IR-unexposed MPN patients as there was also a trend toward higher JAK2 mutation frequency in IR-unexposed vs exposed patients with PV (92.9% vs 65%, P = .1014). MPN patients who were JAK2 V617F-negative were tested for MPL and CALR gene mutations ( Figure 1B ; Supporting Information and CALR mutation frequencies in unexposed to IR MPN patients in this study were similar to the reported data. 9, [32] [33] [34] [35] [36] [37] The frequency of MPL W515 gene mutation was lower in MPN patients in our study, in comparison to published data. Tables S5 and S6 ).
Among the subset of IR-exposed patients negative for mutations in JAK2, MPL, and CALR (TN), recurrently affected genes were EZH2, DNMT3A, TET2, and ATM. Genes affected in single cases in this IRexposed TN subset were KIT, SUZ12, CUX1, KRAS, UMODL1, CBL, and SF3B1 ( Figure 2A) . Overall, the gene functions most frequently affected in these 30 PMF patients are involved in signal transduction, DNA damage, splicing, and epigenetic regulation ( Figure 2C ).
| Copy number alterations and cnLOH in IRexposed and IR-unexposed PMF patients
Analysis of copy-number alterations and cnLOH for 30 PMF patients was assessed by High-Density Array Assay in addition to WES. This revealed frequent alterations, but no significant difference in the rates of copy-number loss, copy-number gain, cnLOH, or multiple chromosomal alterations, respectively in the IR-exposed vs unexposed groups (30.8% vs 47.1%, P = .4651; 15.4% vs 17.6%, P = 1; 38.5% vs 70.6%, P = .1376; and 30.8% vs 47.1%, P = .4651) ( Figure 2D and Table 1 ).
The most common chromosomal abnormalities were cnLOH at 1p, 9p, 11q, and copy-number loss at 7q, 13q. These findings are consistent with published data indicating that the most frequent chromosomal abnormalities in MPNs are LOH at 1p, 9p, 14q, gain of chromosome 8, 9, 14, gain at 1q, and loss at 11q, 13q, 18p, 20q, while loss at 5q, 7p, 7q, and LOH at 17q have been observed in single cases.
41,42
The cnLOH we found at 1p in IR-unexposed PMF patients dupli- cnLOH at 11q duplicated an additional missense mutation CBL R420G
(89% allele frequency) with enhancing cell survival capacity, but without confirmed influence on cell proliferation. 43 Finally, copy-number loss of TP53 at 17p was identified in 1 JAK2-positive (24% allele frequency) unexposed PMF patient in conjunction with a likely pathogenic missense variant p.C176Y (c.527G > A) (23% allele frequency), which suggests its contribution to the disease evolution due to loss of DNA repair function.
| Targeted sequencing of candidate driver genes in TN MPN patients
Based on the WES and high-density array assay data we identified 309 genes that were altered in at least 1 case and may be pathogenic.
To identify novel sequence variants that may drive MPN development in TN patients, we performed targeted sequencing of the 309 genes on an additional cohort of IR-exposed (12) and unexposed (16) TN MPN patients' DNA. In parallel we similarly examined 89 IRunexposed healthy controls to identify germline SNPs or sequence variants that may be unique to the Ukrainian population. We also examined 96 IR-exposed healthy controls to further identify novel SNPs or sequence variants and potentially find evidence of subclinical MPN ( Figure 1A) . 
| Recurrently affected genes in TN IR-exposed MPN patients
We next combined WES and Targeted Sequencing data to focus on TN cases (negative for usual mutations in JAK2, MPL, and CALR genes) ( Figure 3A) . First, we asked whether there are recurrently affected genes that are specific to TN IR-exposed MPN patients. Several potentially pathogenic sequence variants were detected exclusively in TN IR-exposed MPN patients in the following genes: KIT, JAK3, USP6, RBPJL, and RBM44 ( Figure 3A) . One PMF patient (ID 547) harbored
KIT D816V missense mutation with 16% allele frequency reported in patients with systemic mastocytosis. 44 
FIGURE 2
Frequencies of genes with variants considered as pathogenic or potentially pathogenic in (A) IR-exposed and (B) IR-unexposed PMF patients with known driver mutation (black) and in TN patients (white) as identified by WES of PBMC. C, Pathways potentially affected in IRexposed (black) and unexposed (white) PMF patients. D, Copy-number alterations and cnLOHin 13 PMF patients previously exposed to IR and in 17 unexposed PMF patients. IR, Ionizing radiation; PMF, primary myelofibrosis; TN, patients negative for usual driver mutations in JAK2, MPL, and CALR genes; Chr, chromosome; cnLOH, copy-nutral loss of heterozygosity; LOSS, copy-number loss; GAIN: copy-number gain 
| Recurrently affected genes in TN IR-exposed and IR-unexposed MPN patients
We next identified recurrently affected genes that were exclusive to TN cases (IR-exposed or unexposed), which included SF3B1, ATMIN, BCORL1, CSMD1, SEPT9, RBM6, and MEGF6. One of the identified SF3B1 variants was a missense mutation K700E with 32% allele frequency in an unexposed TN PMF patient (ID 1007). K700E, the most frequently reported mutation in the SF3B1 gene, has been identified in chronic lymphocytic leukemia, myelodysplastic syndrome, breast, and pancreatic cancers. [45] [46] [47] [48] 3.8 | Recurrently affected genes in TN IR-exposed and IR-unexposed MPN patients also identified in nonTN cases
Several recurrently affected genes in TN MPN patients (IR-exposed or unexposed) were also involved in MPN patients with usual driver mutations in JAK2, MPL or CALR genes. Among them were ASXL1, ATM, DNMT3A, EZH2, SUZ12, TET2, RTEL1, SETBP1, U2AF1, CSF3R, and UMOD1 ( Figure 3A) . Although mutations of ASXL1 and DNMT3A
were found in cases with usual driver mutations, they were more frequent in TN MPN patients, and only in the IR-exposed TN MPN patients. ASXL1 variants were found in 5 (29.4%) IR-exposed TN cases with allele frequencies varying from 27% to 56%, and DNMT3A variants were found in 3 (17.6%) IR-exposed TN cases with allele frequencies varying from 26% to 48%.
Two sequence variants of the recurrently affected CSF3R gene were identified in IR-exposed (ID 1360) and unexposed (ID 879) TN ET patients. CSF3R T618I (observed in ID 1360 with 37% allele frequency) is a highly prevalent and well-studied specific mutation in chronic neutrophilic leukemia. 49, 50 The other patient (ID 879) had a previously undescribed missense variant CSF3R G415R (46% allele frequency) and in addition TP53 V31I variant (45% allele frequency) which has been previously identified in patients with acute myeloid leukemia. 51 Finally, noncanonical mutations in JAK2 gene were identified in 2 TN cases. JAK2 R938Q missense variant with 45% allele frequency was detected in a IR-exposed TN PMF patient (ID 1283) The JAK2
R938Q somatic mutation was reported previously in a hereditary thrombocythemia case and B-cell acute lymphoblastic leukemia case. 52, 53 An IR-exposed PV patient (ID 1887) exhibited a frameshift variant JAK2 K539 f. of uncertain biological significance with 23% allele frequency.
We also identified potentially pathogenic variants in a healthy 68-years old female who was exposed to IR (documented dose 50 mSv). These were missense U2AF1 p.Q157P (c.470A > C) with 23% allele frequency and nonsense DNMT3A p.C368X (c.C1104A) mutations with 21% allele frequency. U2AF1 p.Q157P (c.470A > C) was previously reported in patients with MDS 54, 55 and PMF. 56 Interestingly, a daughter of this woman was diagnosed with acute leukemia. We did not identify any potential pathogenic variants in healthy IR-unexposed controls.
| DISCUSSION
In this study, we evaluated the effect of prior exposure to IR during the Chernobyl nuclear accident on the clinical characteristics and genomic profiles of MPN patients in Ukraine. IR-exposed MPN patients exhibited a higher mean age and were predominantly men, which likely reflect the time elapsed from the Chernobyl disaster and the male sex-bias of cleanup workers. The clinical profiles of the IRexposed and unexposed patients were similar, although the rate of transfusion-dependence was slightly higher among IR-exposed MPN patients. We found that IR-exposed MPN patients exhibited a different genetic profile from that of unexposed MPN patients: a lower rate of JAK2 V617F mutation, a higher rate of type 1-like CALR mutation, a higher rate of TN cases, and a higher rate of potentially pathogenic sequence variants. No difference in the rates of chromosomal alterations in the IR-exposed and unexposed groups may be related to the fact that some of the patients who developed chromosomal alterations immediately following IR exposure >30 years ago developed leukemia and did not survive to be included in this cohort.
Using Next Generation Sequencing, we identified a spectrum of affected genes with sequence variants in both IR-exposed and Ukrainian population. Supporting the argument that the nonsynonymous sequence variants in potential MPN driver genes that we identified in MPN patients were somatic, rather than germline, none of these sequence variants were identified in unexposed healthy controls. Despite these limitations, we have identified a wide spectrum of nonsynonymous sequence variants among IR-exposed and unexposed MPN patients. We found that while TN IR-exposed and unexposed MPN patients often exhibited similar DNA alterations suggesting a common molecular basis for MPN development, there were unusual genetic variants specific to some of the IR-exposed TN MPN patients and that TN MPN is more common among IR-exposed MPN patients.
These findings indicate that IR exposure contributes particularly to the development of TN MPN, which in turn is driven by a diversity of oncogenic genomic alterations. 
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